Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1101 vs Avastin in First-line Non-squamous NSCLC
NCT03169335Phase 3Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Mar 2017
- Primary completion
- Jun 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of QL1101 in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Qilu Pharmaceutical. Started Mar 2017; status: completed.
02
Drugs
QL1101
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT03169335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03169335.